Leidy NK, Jonas D, Silberman C, Heyes AE. What role do symptoms play in health-related quality of life? Poster presented at the 8th Annual Conference of the International Society for Quality of Life Research; November 2001. Amsterdam, The Netherlands.
Jonas D, Leidy NK, Silberman C, Margolis MK, Heyes AE. Cognitive factors in symptom assessment: are we asking too much? Poster presented at the 8th Annual Conference of the International Society for Quality of Life Research; November 2001. Amsterdam, The Netherlands.
Sorensen SV, Chambers M, Heyes AE. An economic model for the pharmacological management of advanced non-small cell lung cancer in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2001. Cannes, France. [abstract] Value Health. 2001 Sep; 4(6):403.
Njue AI, Feng X-P, Prichard RK. Ivermectin resistance and the glutamate-gated chloride channels in the cattle nematode cooperia oncophora. Poster presented at the 18th International Conference of the World Association for the Advancement of Veterinary Parasitology; August 2001.
Buchner DA, Graboys TB, Johnson K, Mordin MM, Goodman L, Partsch DS, Goss TF. Development and validation of the ITG Health-Related Quality-of- Life Short-Form measure for use in patients with coronary artery disease. Integrated Therapeutics Group. Clin Cardiol. 2001 Aug;24(8):556-63.
Yang J, Bogerd HP, Wang PJ, Page DC, Cullen BR. Two closely related human nuclear export factors utilize entirely distinct export pathways. Mol Cell. 2001 Aug;8(2):397-406.
Shah S, Sesti AM, Chopra T, McLaughlin-Miley C, Copley-Merriman K. Quality of life terminology documented in package inserts. Mapi Quality of Life Newsletter. 2001 Jul;27:1-3.
Njue AI, Prichard RK. Ivermectin resistance in cooperia oncophora and beta-tubulin. Poster presented at the 46th Annual Meeting of the American Association of Veterinary Parasitologists; July 2001.
Anderson H, Espinosa E, Lofts F, Meehan M, Hutchinson G, Price N, Heyes AE. Evaluation of the Chemotherapy Patient Monitor: an interactive tool for facilitating communication between patients and oncologists during the cancer consultation. Eur J Cancer Care (Engl). 2001 Jun;10(2):115-23.
Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy - Lung (FACT-L): analysis of ECOG 5592 data. Poster presented at the 7th Central European Lung Cancer Conference; June 2001. Prague, Czech Republic. [abstract] Lung Cancer. 2001 May; 32(Suppl 1):52.
Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Wolf MK. What is a clinically meaningful change (CMC) on the functional assessment of cancer therapy - lung (FACT-L): analysis of ecog 5592 data. Poster presented at the 37th Annual Meeting of the American Society of Clinical Oncology; May 2001. San Francisco, CA.
Leidy NK, Jonas D, Margolis MK, Heyes AE, Jones K, Silberman C. On health-related quality of life, symptoms and the complementary nature of two patient-reported outcomes. Presented at the Drug Information Association Symposium of Contributed Papers on Quality of Life Evaluation; March 2001. Hilton Head, SC.
Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Bonomi P, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy (lung) (FACT-L): analysis of ECOG 5592 data. Lung Cancer. 2001;373-6.